14
Participants
Start Date
July 26, 2017
Primary Completion Date
July 28, 2020
Study Completion Date
August 2, 2022
Nivolumab
nivolumab administered IV over 60 minutes at 1 mg/kg every 3 weeks for 4 treatment cycles (Induction) then continue with nivolumab administered IV over 60 minutes at 3 mg/kg every 2 weeks
Ipilimumab
ipilimumab administered IV over 90 minutes at 3 mg/kg every 3 weeks for 4 treatment cycles (Induction)
Memorial Sloan Kettering Cancer Center, New York
Lombardi Comprehensive Cancer Center, Washington D.C.
Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C.
H. Lee Moffitt Cancer Center and Research Institute, Tampa
John Theurer Cacner Center at Hackensack University Medical Center, Hackensack
Collaborators (1)
Melanoma Research Foundation Breakthrough Consortium
OTHER
Bristol-Myers Squibb
INDUSTRY
University of Colorado, Denver
OTHER
University of California, San Francisco
OTHER
Vanderbilt University
OTHER
Columbia University
OTHER
University of Pittsburgh
OTHER
Yale University
OTHER
M.D. Anderson Cancer Center
OTHER
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Memorial Sloan Kettering Cancer Center
OTHER
Northwestern University
OTHER
Dana-Farber Cancer Institute
OTHER
Georgetown University
OTHER